Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor
Virology, ISSN: 0042-6822, Vol: 556, Page: 73-78
2021
- 25Citations
- 31Usage
- 57Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations25
- Citation Indexes23
- 23
- CrossRef17
- Patent Family Citations2
- Patent Families2
- Usage31
- Downloads28
- Abstract Views3
- Captures57
- Readers57
- 57
Article Description
The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0042682221000180; http://dx.doi.org/10.1016/j.virol.2021.01.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85100429972&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33548599; https://linkinghub.elsevier.com/retrieve/pii/S0042682221000180; https://ecommons.luc.edu/math_facpubs/51; https://ecommons.luc.edu/cgi/viewcontent.cgi?article=1051&context=math_facpubs; https://dx.doi.org/10.1016/j.virol.2021.01.010
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know